TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at least 18 years or older with moderate to severe pain that requires around the clock opioid therapy. Subjects must report constipation caused or aggravated by opioids.~Exclusion Criteria:~* Females who are pregnant or lactating.~* Subjects with evidence of any clinically unstable disease or subjects with evidence of impaired liver/kidney function upon entry into the study.~* Subjects with evidence of significant structural abnormalities of the gastrointestinal tract.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* females of non-childbearing potential or postmenopausal;~* history of COPD as defined by ATS/ERS criteria;~* moderate COPD responsive to ipratropium and salbutamol;~* current smoker or ex-smoker.~Exclusion criteria:~* no instable COPD; max 1000 mcg inhaled steroids per day; no B-blockers

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Japanese participant must be 18 years or older at the time of signing the informed consent.~* Participants who have a clinical diagnosis of aTTP (initial or recurrent), which includes thrombocytopenia (defined as platelet count \<100,000/µL), microangiopathic hemolytic anemia as evidenced by red blood cell fragmentation (eg, presence of schistocytes), and increased levels of LDH~* Participants who require initiation of daily PE treatment and have received a maximum of 1 PE treatment prior to enrollment in the study~* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies~* Capable of giving signed informed consent~Exclusion criteria:~* Platelet count ≥100,000/µL,~* Serum creatinine level \> 2.3mg/dL in case platelet count is \> 30,000µL~* Known other causes of thrombocytopenia~* Congenital TTP~* Clinically significant active bleeding or high risk of bleeding~* Malignant arterial hypertension~* Known chronic treatment with anticoagulant treatment that cannot be stopped~* Participants who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown~* Participants currently or less than 28 days prior to enrollment in this study, enrolled in a clinical study with another investigational drug or device~* Clinical condition other than that associated with TTP, with life expectancy \< 6 months, such as end-stage malignancy~* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study~* Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caplacizumab (Type: EXPERIMENTAL): Eligible study participants will receive caplacizumab in addition to standard of care such as daily plasma exchange (PE) and corticosteroid treatment (mandatory), immunosuppressive treatment (if needed)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must sign an informed consent before of specific procedures of clinical trial.~* Patients with histologically confirmed breast cancer and overexpression of Her2neu.~* Age\> 18 years.~* Eastern Cooperative Oncology Group (ECOG) equal or \< 2.~* Patients have not been treated previously with chemotherapy for metastatic disease.~* Patients must have at least one measurable lesion according to RECIST criteria.~* Patients should have an adequate organ function to tolerate chemotherapy.~Exclusion Criteria:~* Patients with hypersensitivity reactions to any of the medications of the clinical trial.~* Patients who are pregnant or lactating are not eligible.~* Hepatic disease.~* Not controlled active infection~* Symptomatic metastatic brain cancer~* Previous adjuvant treatment with anthracyclines with a total accumulated dose \> 300 mg/m2 (Doxorubicin) or \> 600 mg/m2 (Epirubicin)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Caelyx,Cyclophosphamide,Trastuzumab (Type: OTHER): Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pain \> 6 months~* Long term use of opioids~* Major surgery~Exclusion Criteria:~* Use of regional anesthetic techniques~* No need for intravenous (IV) patient controlled analgesia (PCA) after surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: ACTIVE_COMPARATOR): Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer.~* Patients must be considered unresectable or inoperable.~* Patients must be 18 years of age or older.~* Patients must have a Karnofsky performance (A measure general well-being and activities of daily life. Scores range between 0 and 100 where 100 represents normal and 0 represents death.) of score \> or = to 70.~* Patients must have adequate organ and marrow function.~* Patient must be willing to use effective contraception if female with reproductive capability.~* Patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.~Exclusion Criteria:~* Patients with any component of small cell lung carcinoma~* Patients with evidence of a malignant pleural or pericardial effusion~* Prior radiotherapy to the thorax such that composite radiation would significantly overdose critical structures, either per estimation of the treating radiation oncologist or defined by failure to meet normal tissue tolerance constraints~* Patients cannot tolerate concurrent chemotherapy~* Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects.~* Prisoners are excluded for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Response-driven Adaptive RT (Type: EXPERIMENTAL): Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Wall thickness ≥ 15 mm in one or more myocardial segments that is not explained by loading conditions.~* LVOT gradient \> 30 mmHg at rest and/or \> 50 mmHg at Valsalva's maneuver or exercise~* New York Heart Association Functional class (NYHA) ≥ II~Exclusion Criteria:~* Age \< 18 years~* Known allergy to trial medicine~* Contraindications to beta-blocker treatment~* Contraindications to Magnetic resonans scan, including contraindication to the contrast agent gadolinium.~* Female patients who are pregnant (positive plasma-HCG), breastfeeding or of child-bearing potential while not practicing effective chemical contraceptive hormones.~* In case of patients having a pacemaker, they may not be pace-dependent.~* Treatment with Amiodarone~* Atrial fibrillation/flutter at the time of examination~* Bradycardia \< 49 beats/min~* Systolic blood pressure \< 100 mmHg~* Trifascicular block~* Previous transcoronary ablation of septum hypertrophy (TASH) or myectomy~* Current abuse of alcohol and/or drugs~* Significant co-morbidity or issues that makes the patient unsuitable for participation, judged by the investigator~* Patients who cannot give valid consent (e.g. mental illness or dementia)~* Patients who do not understand danish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoprolol Succinate (Type: ACTIVE_COMPARATOR): Metoprololsuccinat
- Placebo oral capsule (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting over the age of 18 requiring hemodialysis via CVCs were eligible.~Exclusion Criteria:~* Having a poor venous system with inadequate blood flow for appropriate HD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal Saline Catheter Lock Solution Group (Type: ACTIVE_COMPARATOR): Patients receiving normal saline catheter locking solution
- Sodium Bicarbonate Catheter Lock Solution (Type: ACTIVE_COMPARATOR): Patients receiving sodium bicarbonate catheter locking solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven squamous cell cancer of the oropharynx or hypopharynx~  * T4 and nonresectable OR~ * T3 extended to oropharynx or hypopharynx and nonresectable~ * N0-3 (stage III or IV)~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Greater than 3 months~Hematopoietic:~* Neutrophil count at least 2000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.25 times upper limit of normal (ULN)~* Transaminases no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 1.25 times ULN~Cardiovascular:~* No severe cardiac disease~Other:~* No prior malignancy except basal cell skin cancer~* No uncontrolled infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~* No concurrent antineoplastic therapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* No prior surgery (except biopsy or adenectomy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed gastric adenocarcinoma,diagnosed as locally advanced gastric cancer and primary tumor invades or penetrates serosa~* Ambulatory males or females, aged 18-80 years old~* ECOG score 0-2~* Given informed consent~* Life expectancy more than 3 months~* Measurable lesion~* Normal cardiac, hepatic, renal, and bone marrow function(WBC:3.5×10\^9/l\~12×10\^9/l;PLT:\>100×109/l;Bil:\<1.5 fold of upper limit value; ALT/AST:\<2.5 fold of upper limit value;Ccr:\>80ml/min;Cr:1.5mg/dl)~Exclusion Criteria:~* Prior stomach surgery~* Previous cytotoxic chemotherapy, radiotherapy, target therapy or immunotherapy for any tumor~* History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix~* distant metastasis(such as No.16 and No.13 lymphnode,liver, lung,brain,bones or peritoneal metastasis)~* Severe bleeding~* Bowel obstruction, ileus or complete pyloric obstruction~* Serious uncontrolled concomitant disease~* History of myocardial infarction in 6 months~* Woman with on-going pregnancy or breast-feeding, or contemplating pregnancy~* Systemic treatment with corticosteroid~* Patients judged inappropriate for the trial by the physicians

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOX (Type: ACTIVE_COMPARATOR): None
- SOX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Is a healthy male or female (to be confirmed by medical history);~* Is 18 years of age or older;~* In the case of a female of childbearing potential, is using two acceptable forms of birth control;~* In the case of a female of childbearing potential, has a negative urine pregnancy test (UPT) at Day 1 and are willing to submit to a UPT at the end of study (EOS);~* Is free of any systemic or dermatological disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events (AEs);~* Is of any Fitzpatrick Skin Type or race, providing the skin pigmentation will allow discernment of erythema~Key Exclusion Criteria:~* Has a history of photosensitivity or photoallergy;~* Has any visible skin disease at the application site which, in the opinion of the Investigator, will interfere with the evaluation of the test site reaction;~* Is using systemic/topical corticosteroids within 3 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study;~* Is not willing to refrain from using systemic/topical anti-inflammatory analgesics such as aspirin (occasional use of acetaminophen will be permitted);~* Is taking medication known to cause phototoxic reactions (eg, tetracyclines, thiazides, nonsteroidal anti-inflammatory drugs \[NSAIDs\]);~* Has psoriasis and/or active atopic dermatitis/eczema;~* Has known sensitivity or allergy to constituents of materials being evaluated including diacerein, mineral oil, petrolatum, cetyl alcohol, D\&C Yellow #10 and/or ethyl paraben;~* Has damaged skin in or around the test sites, including sunburn, excessively deep tans,uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;~* Has received treatment for any type of internal cancer within 5 years prior to study entry;~* Has any known sensitivity to adhesives; and/or~* Has received any investigational drug(s) within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single Cohort (Healthy Volunteers) (Type: EXPERIMENTAL): Single cohort received diacerein 1% ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Participant was \>20 years and \<75 years of age on the index date (i.e., the date of initiating MK-0954A therapy)~* Diagnosed with hypertension and had received MK-0954A 50/12.5 mg for at least 3 months~* Had at least one serum uric acid measurements at baseline and one at 3 months after using MK-0954A 50/12.5 mg~* Had the following records documented in the chart during the data collection period:~  * medical history and co-morbidities (if available)~ * sitting blood pressure, serum uric acid, lipid profile test results before and after using MK-0954A 50/12.5 mg~ * serum electrolytes, serum creatinine, and pre-meal sugar (if available)~ * prescription information of all antihypertensive regimens~Exclusion criteria:~* Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg~* Serum creatinine \>2 mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- All Participants (Type: None): Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete